Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Business & Industry
- Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries
- Moderna announces emergency use listing granted by the World Health Organization for its COVID-19 vaccine
- Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra®
- Moderna announces additional investments to increase global supply for COVID-19 vaccine to up to 3 billion doses in 2022
- Pfizer acquires Amplyx Pharmaceuticals
Research & Development
- Our immune systems blanket the SARS-CoV-2 spike protein with antibodies
- Using personalized medicine to avoid resistance to leukemia treatment
- Speeding new treatments
- Large collaboration creates cell atlas of COVID-19 pathology
- Brazilian coronavirus variant likely to be more transmissible and able to evade immunity
- Hepatitis C drugs multiply effect of COVID-19 antiviral Remdesivir
- How COVID-19 impacted UK healthcare
Conferences & Events
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
- FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review
- FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
- Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
- AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
- Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna